Member Area

Bulletin .

A newsletter about cannabis and cannabinoids as medicine

2022
  • Published
    Last updated

    IACM-Bulletin of December 18, 2022

    🏷️ Science/Human — Cannabis may be helpful in the treatment of post-traumatic stress disorder

    A case-series of patients with post-traumatic stress disorder from the UK Medical Cannabis Registry was analyzed. Investigators from Imperial College Medical Cannabis Research Group from the Department of Surgery and Cancer of Imperial College London, UK, observed an improvement of health-related quality of life, which was assessed at 1-, 3-, and 6-months using validated patient reported outcome measures.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of December 4, 2022

    🏷️ Science/Human — Cannabis may be helpful in the treatment of children with autism

    A study with 14 participants conducted at Melbourne's Monash Children's Hospital, Australia, has supported the benefits of using medicinal cannabis as a treatment for children diagnosed with autism spectrum disorder. The phase I trial, which was designed to assess product safety, discovered "significant changes" in the symptoms and behaviours of the 14 participants.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of November 19, 2022

    🌐 USA — Voters in Maryland and Missouri approved the legalisation of cannabis for use by adults

    On 8 November residents of five U.S. states voted on whether to legalize cannabis for adults. A growing number of states have legalized cannabis in recent years despite the drug remaining illegal under federal law. The proposals passed in Maryland and Missouri.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of November 5, 2022

    🏷️ Science/Human — Cannabis may be helpful in the treatment of emotionally unstable personality disorder according to a case series

    Six out of 7 patients diagnosed with emotionally unstable personality disorder showed symptom improvement with cannabis-based medicines. They were treated at Zerenia clinics in the United Kingdom and Colombia receiving either cannabis extracts or cannabis flowers with varying THC and CBD content. Patients had trialled at least one medication and one form of psychotherapy.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of October 23, 2022

    🏷️ IACM — The IACM honoured four researchers at the Cannabinoid Conference 2022

    At the Cannabinoid Conference 2022 which took place in Basel, Switzerland, the IACM honoured four persons for special achievements regarding the re-introduction of cannabis and cannabinoids as medicine. The IACM Award 2022 for Clinical Research went to Philip McGuire, the IACM Ester Fride Award for Basic Research 2022 went to Andreas Zimmer, the IACM Award 2022 for Young Researchers went to Arnau Busquets Garcia, and the IACM Special Award 2022 went to Allyn Howlett.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of October 9, 2022

    🌐 USA — President Joe Biden pardons thousands of people with federal offenses for simple cannabis possession

    President Joe Biden took steps to overhaul U.S. policy on cannabis on 6 October by pardoning thousands of people with federal offenses for simple cannabis possession and initiating a review of how the drug is classified. He said thousands of people with prior federal convictions could be denied employment, housing or educational opportunities and his executive action would relieve such "collateral" consequences.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of October 6, 2022

    🏷️ IACM — Only 2 weeks until the start of the Cannabinoid Conference 2022

    On October 20-21, the leading international conference on the medical use of cannabis and cannabinoids will be held at the Congress Center Basel, Switzerland.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of September 25, 2022

    🏷️ Science/Human — Cannabis may improve autism symptoms

    In a study with a cannabis extract containing a ratio of THC to CBD of 1 to 20 children with autism spectrum disorder showed significant improvement. The study was conducted by investigators of Azrieli National Centre for Autism and Neurodevelopment Research at Ben Gurion University in Beer Sheva, Israel, and other Israelian universities. “Parents were instructed to start with one drop daily (each drop contains: 0.3 mg THC and 5.7 mg CBD) and increase the dosage gradually until they perceived improvements in their child’s behavior such as decreased irritability, aggressiveness, hyperactivity, and/or sleep disturbances.” Patients received the extract for 6 months in an open study, which was completed by 82 participants.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of September 11, 2022

    🏷️ IACM — Conference attendees to receive additional free IACM membership

    Attendees at the upcoming Cannabinoid Conference 2022 on Oct. 20-21 in Basel, Switzerland, will receive a free membership to the new IACM. The IACM is undergoing a restructuring. The old IACM has been dissolved, and the successor organization is nearing completion of its new formation. IACM members who have already paid their dues this year will receive a code in a few days that will give them a reduction in their normal individual rate.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of August 28, 2022

    🏷️ Science/Human — Cannabis improves abdominal pain in gastroparesis

    In a study at Westchester Medical Center in Valhalla, USA, with 24 patients suffering from gastroparesis both isolated THC and cannabis improved symptoms. Gastroparesis is characterised by delayed gastric emptying due to weak muscle constructions of the stomach. Six patients were prescribed pure THC, ten cannabis and eight pure oral THC followed by cannabis.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of August 14, 2022

    🏷️ Science/Human — Many women use cannabis for the treatment of menopause-related symptoms

    In a study with 285 women with menopause-related symptoms many participants used cannabis. It was conducted by researchers of the Department of Psychiatry of Harvard Medical School in Boston, USA. Participants (perimenopausal, n = 131; postmenopausal, n = 127) completed assessments of menopause-related symptomatology and cannabis use

    Read more →
  • Published
    Last updated

    IACM-Bulletin of July 31, 2022

    🏷️ IACM — Cannabinoid Conference 2022 in October in Switzerland

    On 20 to 21 October the leading international conference on medical uses of cannabis and cannabinoids takes place in the Congress Centre Basel, Switzerland. Don’t miss this opportunity to meet the leading researchers in the field, learn from their experience, exchange with others and get first-hand and latest information! This year we are holding the conference in cooperation with the Swiss Society for Cannabis in Medicine. In Switzerland, the medical use of cannabis was recently legalised.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of July 17, 2022

    🏷️ Science/Human — Very low doses of a THC-rich cannabis extract improved memory in a patient with Alzheimer's disease

    Investigators of the Federal University for Latin American integration in Foz do Iguaçu, Brazil, and Johns Hopkins University in Baltimore, USA, presented a case report of a 75-year-old man in an early stage of Alzheimer’s disease, who profited from very low doses of THC rich cannabis. He presented with main symptoms of memory deficit, spatial and temporal disorientation, and limited daily activity. The treatment was carried out for 22 months with microdoses of a cannabis extract containing THC and CBD. The patient received it daily for 22 months with the daily dosage never exceeding 1 mg of THC per day.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of July 3, 2022

    🌐 Switzerland — The medical use of cannabis will be legal from August 2022 on

    The Swiss government on 22 June decided to lift the ban on cannabis for medical use from 1 August. Patients who are medically prescribed the drug will no longer need to seek exceptional permission from the health ministry. The sale and consumption of cannabis for non-medical purposes will remain prohibited.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of June 19, 2022

    🌐 Brasil — Superior Court of Justice authorised 3 patients to grow cannabis for medical treatment

    A top court in Brazil on 14 June authorized three patients to grow cannabis for medical treatment, a decision that is likely to be applied nationwide in similar cases. A five-judge panel of the country’s Superior Court of Justice unanimously agreed that the three patients can grow cannabis and extract its oil for use in pain relief. Brazilian law currently limits the medical use of cannabis derived products to imported goods.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of June 5, 2022

    🏷️ Science/Human — Cannabis may be helpful in the treatment of nausea according to an app based study

    Using an app, where Herr patients can enter their symptom changes, by 886 people cannabis was helpful in the treatment of nausea. The research was conducted by investigators of the College of pharmacy at the University of New Mexico in Albuquerque, USA. Participants completed 2220 cannabis self-administration sessions intended to treat nausea between 2016 and 2019.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of May 22, 2022

    🏷️ Science/Human — Cannabis may be helpful against cancer pain according to an open study

    In an open study with 24 cancer patients, who received capsules with traditional cannabis leaves powder, investigators observed improvements in pain and quality of life. It was conducted by the Department of Dravyaguna of GJ Patel Institute of Ayurvedic Studies and Research in New Vallabhvidyanagar of the state of Gujarat, India. Participants received the powder in a dose of 250 mg thrice daily and 50 mL of cow’s milk and 4 g of crystal sugar for 4 weeks.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of May 8, 2022

    🏷️ IACM — Cannabinoid Conference 2022

    The IACM Board would like to invite you to attend the Cannabinoid Conference 2022 and present your research results. The event will take place from 20-21 October 2022 in Basel, Switzerland. The conference will be held in cooperation with the Swiss Society for Cannabis in Medicine.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of April 24, 2022

    🏷️ Science/Human — Cannabis may be helpful in inflammatory bowel disease according to survey

    According to a survey with 417 patients suffering from inflammatory bowel disease cannabis may be helpful in symptom management. Mean age was 41 years and about 55% suffered from ulcerative colitis, while about 43% from Crohn’s disease. 17.5% of respondents to the survey indicated that they had used cannabis for recreational purposes in the past. 7.5% said that they were currently using cannabis products either illegal or prescribed by a doctor.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of April 10, 2022

    🏷️ IACM — The Cannabinoid Conference 2022 is dedicated to Daniela Parolaro

    The upcoming Cannabinoid Conference on 20-21 October 2022 in Switzerland is dedicated Dr Daniela Parolaro, who passed away in March 2022. For many years Dr Parolaro served as a member of the IACM Board of Directors and was Chairwoman of the IACM from 2013 to 2015.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of March 27, 2022

    🏷️ Science/Human — Cannabis may be helpful in Tourette syndrome according to an open study

    In an open perspective study with 18 adult patients suffering from Tourette syndrome cannabis reduced symptoms after 4 and 12 week of treatment. It was conducted at the Department of Neurology of the Tel-Aviv Sourasky Medical Center, Israel. The mode of cannabis therapy was decided by the treating neurologist. The most common mode of administration was smoking (80%).

    Read more →
  • Published
    Last updated

    IACM-Bulletin of March 13, 2022

    🌐 Costa Rica — The medical use of cannabis is now legal

    On 2 March medicinal cannabis was legalized in Costa Rica with the president’s signing of a law passed a day earlier by congress. The law also legalizes the cultivation and industrial production of hemp. Recreational marijuana use continues to be prohibited. The law is similar in allowing medicinal use to laws passed in other countries in the region, including: Argentina, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru and Uruguay. Uruguay also legalized recreational use.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of February 27, 2022

    🏷️ Science/Human — Cannabis treatment is associated with improved quality of life according to a large study

    An analysis of data from approximately 10,000 patients, who received cannabis in Israel, cannabis treatment was associated with high adherence to the therapy, improvement in quality of life and decreased pain with a low frequency of serious adverse events. Researchers of the Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel, investigated safety and effectiveness of the treatment at 6 months.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of February 13, 2022

    🌐 USA — Mississippi becomes the 37th state to legalise the medical use of cannabis

    Mississippi joined 36 other U.S. states in legalizing cannabis for medical use on 2 February, as the governor signed legislation permitting cannabis for treatment of severe health conditions such as cancer, AIDS and Alzheimer's disease. Announcing enactment of the bill, Governor Tate Reeves said the final version passed last week by the Republican-controlled legislature was designed to curb recreational cannabis use, such as by allowing patients to obtain no more than 3 ounces of cannabis per month, or 3.5 grams a day.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of January 30, 2022

    🏷️ Science — Basic research on cannabinoids in COVID 19 should be interpreted with caution

    Basic research suggests that some non-psychoactive cannabinoids may be helpful for the prevention and treatment of infection with the new coronavirus. In recent years several research reports have been presented also in the IACM-Bulletin, the latest in the first bulletin of January 2022.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of January 16, 2022

    🏷️ Science/Cells — Cannabinoids may have the potential to prevent and treat infection by the new coronavirus

    Investigators at the Linus Pauling Institute at the Department of Pharmaceutical Sciences of the College of Pharmacy of the Oregon State University, USA, reported that two cannabinoids, CBDA (cannabidiolic acid) and CBGA (cannabigerolic acid) may prevent the infection of human epithelial cells with the SARS-CoV-2 virus, which is responsible for the current COVID-19 pandemic.

    Read more →
  • Published
    Last updated

    IACM-Bulletin of January 2, 2022

    🏷️ Science/Human — The medical use of cannabis may be helpful in severe treatment resistant epilepsy

    In 10 children with treatment resistant epilepsy a range of whole cannabis extracts were effective in reducing seizure frequency. Investigators from DrugScience, London, the Department of Brain Sciences of Imperial College London, London, and the London School of Economics and Political Science, UK, reported the results in British Medical Journal Paediatrics Open. Participants were recruited from two charities that support children who are using medical cannabis to treat their epilepsies. Individual dosing regimens were determined by clinicians.

    Read more →